Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that its market approval filing for relmapirazin, a Category 1 chemical drug and fluorescent tracer for measuring glomerular filtration rate (GFR), has been accepted for review by the National Medical Products Administration (NMPA). This tracer is designed for use in individuals with both impaired and normal renal function.
Relmapirazin was developed by US-based MediBeacon Inc. as part of a comprehensive dynamic monitoring system for GFR assessment. In July 2019, MediBeacon granted Huadong Medicine exclusive commercialization rights for the drug and monitoring system across China, Hong Kong, Taiwan, Singapore, and Malaysia, covering a total of 25 markets in Asia.- Flcube.com
